Boehringer Ingelheim reports 24% leap in 1st-half sales

Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24% to 9.2 billion euros ($10.86 billion) on the same period in the previous year after adjustment for currency effects (+27% in euro terms).

In the first half of the year, family-owned German pharma major Boehringer Ingelheim’s figures for the first time included the net sales of Sanofi’s animal health business, Merial, which was acquired at the start of the year. As expected, this contributed significantly to the strong increase in net sales. However, the human pharmaceuticals and biopharmaceutical contract manufacturing businesses also grew.

Against this background, Boehringer Ingelheim says it continues to expect a considerable year-on-year increase in currency-adjusted net sales for the current year.